


50. The compound of Claim 45, wherein R<sub>3</sub> is *o*-chlorobenzene.
51. The compound of Claim 45, wherein R<sub>3</sub> is 1-naphthalene.
52. The compound of Claim 45, wherein R<sub>3</sub> is 2-naphthalene.

**In the abstract:**

This invention discloses pyrrolo pyrimidine compounds, and pharmaceutically acceptable salts, solvates and prodrugs thereof, of the following formula (3):



These compounds are useful in therapeutically and/or prophylactically treating patients with cancer by inhibiting receptor tyrosine kinases and/or dihydrofolate reductase and/or thymidylate synthase. Methods of using these compounds are also disclosed.

**REMARKS**

Applicant's attorney would like to thank the Examiner for his assistance in the telephone interview of October 10, 2002. Applicant confirms the election of Group II, drawn to pyrrolopyrimidines, without traverse. Applicant cancels herewith Claims 12-14, 21 and 23-28, claims which are withdrawn from consideration, and also cancels Claims 1-11 and 15-20, rejected as drawn to an improper Markush group. New claims, Claims 35-52 are added, drawn only to the elected subject matter and which incorporate the subject matter of Claims 4-11. The pending claims now include Claims 22 and 29-52.

A new abstract is submitted, as well as new pages 20-25. The chemical formulas in the specification and Claims 22 and 29 have been corrected to indicate the proper number of double bonds in the pyrimidine rings. A new page containing Table 4 is also submitted, in which minor spelling corrections were made to the text. The next to last row in Table 4 represents data for a compound known in the art as "VEGF kinase inhibitor", one of the control compounds or standards against which compounds of the present invention are compared. Applicant respectfully submits that with the above remarks and corrections the objections to the specification are overcome.